Impact of an integrated classifier using biomarkers, clinical and imaging factors on clinical decisions making for lung nodules.

ABSTRACT:

Background

An integrated classifier that utilizes plasma proteomic biomarker along with five clinical and imaging factors was previously shown to be potentially useful in lung nodule evaluation. This study evaluated the impact of the integrated proteomic classifier on management decisions in patients with a pretest probability of cancer (pCA) ≤50% in "real-world" clinical setting.

Methods

Retrospective study examining patients with lung nodules who were evaluated using the integrated classifier as compared to standard clinical care during the same period, with at least 1-year follow-up.

Results

A total of 995 patients were evaluated for lung nodules over 1 year following the implementation of the integrated classifier with 17.3% prevalence of lung cancer. 231 patients

SUBMITTER: Kheir F 

PROVIDER: S-EPMC10407524 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature